Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;76(4):E86.
doi: 10.1002/hep.32587. Epub 2022 Jun 22.

Reply

Antonio D'Alessio  1   2 , Claudia Angela Maria Fulgenzi  1   3 , David J Pinato  1   4
Affiliations

Reply

Antonio D'Alessio et al. Hepatology. 2022 Oct.
No abstract available

PubMed Disclaimer

References

    1. D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and child‐Pugh a and B cirrhosis: a real‐world study. Hepatology. 2022;76:1000–12.
    1. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73.
    1. Li M, Kroetz DL. Bevacizumab‐induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–60.
    1. Fessas P, Possamai LA, Clark J, Daniels E, Gudd C, Mullish BH, et al. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. 2020;159(2):167–77.
    1. Pinato DJ, Murray SM, Forner A, Kaneko T, Fessas P, Toniutto P, et al. Trans‐arterial chemoembolization as a loco‐regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9(9):e003311.

LinkOut - more resources